167 related articles for article (PubMed ID: 35945038)
1. Hereditary Transthyretin Amyloidosis Cardiomyopathy: The South Florida Experience.
Trujillo L; Colombo R
Am J Cardiol; 2022 Oct; 180():140-148. PubMed ID: 35945038
[TBL] [Abstract][Full Text] [Related]
2. DISCOVERY: prevalence of transthyretin (
Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
4. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
5. Sex differences among patients with transthyretin amyloid cardiomyopathy - from diagnosis to prognosis.
Patel RK; Ioannou A; Razvi Y; Chacko L; Venneri L; Bandera F; Knight D; Kotecha T; Martinez-Naharro A; Masi A; Porcari A; Brown J; Patel K; Manisty C; Moon J; Rowczenio D; Gilbertson JA; Sinagra G; Lachmann H; Wechalekar A; Petrie A; Whelan C; Hawkins PN; Gillmore JD; Fontana M
Eur J Heart Fail; 2022 Dec; 24(12):2355-2363. PubMed ID: 36575133
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
[TBL] [Abstract][Full Text] [Related]
7. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
[TBL] [Abstract][Full Text] [Related]
8. Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model.
Zuppo Laper I; Camacho-Hubner C; Vansan Ferreira R; Leite Bertoli de Souza C; Simões MV; Fernandes F; de Barros Correia E; de Jesus Lopes de Abreu A; Silva Julian G
PLoS One; 2024; 19(2):e0278738. PubMed ID: 38359001
[TBL] [Abstract][Full Text] [Related]
9. Use of Technetium-99m-Pyrophosphate Single-Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy.
Yu AL; Chen YC; Tsai CH; Wu YA; Su MY; Chou CH; Shun CT; Hsueh HW; Juang JJ; Lee MJ; Tseng PH; Hsu CH; Hsieh ST; Ko CL; Cheng MF; Chao CC; Lin YH
J Am Heart Assoc; 2024 Jan; 13(2):e030512. PubMed ID: 38214277
[TBL] [Abstract][Full Text] [Related]
10. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
[TBL] [Abstract][Full Text] [Related]
11. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
De Bleecker JL; Claeys KG; Delstanche S; Van Parys V; Baets J; Tilleux S; Remiche G
Acta Neurol Belg; 2023 Jun; 123(3):1029-1037. PubMed ID: 36829087
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
[TBL] [Abstract][Full Text] [Related]
13. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
[TBL] [Abstract][Full Text] [Related]
16. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
17. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
18. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
[TBL] [Abstract][Full Text] [Related]
19. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis.
Steinebrei M; Gottwald J; Baur J; Röcken C; Hegenbart U; Schönland S; Schmidt M
Nat Commun; 2022 Oct; 13(1):6398. PubMed ID: 36302762
[TBL] [Abstract][Full Text] [Related]
20. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
